Oral Peptide Delivery & Permeation Enhancers

Executive summary

Oral peptide delivery seeks to replace injectable peptides with tablets or capsules. The central problem is that peptides are large, polar, and susceptible to acid and enzymatic degradation in the gastrointestinal tract, and the intestinal epithelium is a tight barrier. Permeation enhancers are functional excipients that transiently modify that barrier to increase peptide absorption.

The most commercially important example is Rybelsus (oral semaglutide), approved by the U.S. FDA on 2019-09-20 FDA press release. Rybelsus combines semaglutide with salcaprozate sodium (SNAC). The FDA label states that each Rybelsus tablet contains 300 mg SNAC and that oral semaglutide has an absolute bioavailability of approximately 0.4% to 1% Rybelsus FDA label. That low bioavailability is acceptable because the enhancer enables a therapeutic peptide dose to be absorbed from the stomach.

A second FDA-approved product, Mycapssa (oral octreotide capsules), was approved on 2020-06-26 for long-term maintenance treatment in acromegaly patients responding to octreotide Drugs@FDA, NDA 208232. This demonstrates that oral peptide delivery is not a single-product phenomenon, although the field has had many more failures than approvals.

The core intellectual property for SNAC-type enhancers includes granted U.S. Patent No. 5,650,386 A, assigned to Emisphere Technologies, Inc., granted 1997-07-22 US5650386A. A granted patent is evidence of recorded claims; it is not proof of clinical performance or commercial viability.

Technology fundamentals

Why oral peptide delivery is difficult

Peptides face multiple barriers after oral administration. A peer-reviewed review by Maher et al. summarizes the obstacles: gastric acid, luminal and brush-border peptidases, mucus layers, the tight-junction-rich epithelium, cellular efflux systems, and variable gastrointestinal transit Maher et al. 2016, DOI 10.1016/j.addr.2016.06.005.

Permeation enhancers do not solve all of these problems; they primarily address the epithelium barrier and, in some formulations, local pH or enzymatic stability. The key design problem is that the enhancer must increase peptide permeability without producing sustained epithelial damage.

Major enhancer classes

Maher et al. categorize intestinal permeation enhancers into several mechanistic families [Maher et al. 2016, DOI 10.1016/j.addr.2016.06.005]:

• Medium-chain fatty acids and salts — sodium caprate (C10), sodium caprylate (C8), and related compounds. These are among the most clinically studied enhancers.
• N-acylated amino acids — salcaprozate sodium (SNAC), and related Emisphere compounds. This class is the most commercially validated because it is used in Rybelsus.
• Bile salts and bile salt derivatives — sodium glycocholate, sodium taurocholate, and synthetic variants.
• Acyl carnitines — palmitoyl carnitine and related zwitterionic enhancers.
• Chitosan and polymeric enhancers — mucoadhesive polymers that can open tight junctions.
• Protease inhibitors — often combined with enhancers to reduce luminal peptide degradation, though the FDA-approved Rybelsus formulation relies on SNAC rather than a conventional protease inhibitor.

This classification is load-bearing for the technology map; it comes from a single peer-reviewed review and is therefore treated as [SINGLE-SOURCE] for the categorical taxonomy, although individual enhancer examples are widely documented in the patent and regulatory record.

SNAC and the Emisphere approach

SNAC is an amphiphilic N-acylated amino acid derivative. The mechanism of SNAC-based oral semaglutide absorption was characterized in a peer-reviewed Science Translational Medicine paper Buckley et al. 2018, DOI 10.1126/scitranslmed.aar7047. The authors reported that SNAC increased local gastric pH and that semaglutide absorption in the stomach occurred via a transcellular route, rather than through traditionally assumed paracellular tight-junction opening.

This mechanism is consistent with the FDA label instruction that Rybelsus must be taken on an empty stomach with no more than 4 ounces of plain water, and that patients must wait at least 30 minutes before eating, drinking, or taking other oral medicines Rybelsus FDA label. Food or additional liquid alters the local environment required for SNAC-assisted gastric absorption.

The transcellular mechanism is important for safety: it implies that the enhancer does not have to produce broad tight-junction opening to be effective, but the local effect must still be controlled.

Patent vs. mechanism

The original Emisphere patent, U.S. Patent No. 5,650,386 A, is a granted patent, not an application US5650386A. It records claims over carrier/enhancer compositions and methods for oral delivery of active agents. Critically, this patent does not itself demonstrate that a peptide achieves a therapeutic systemic concentration in humans. Patent claims are legal claims to composition and method; clinical feasibility is a separate evidentiary standard.

Clinical and regulatory evidence

Rybelsus: oral semaglutide with SNAC

Rybelsus was approved by the FDA on 2019-09-20 as the first oral GLP-1 receptor agonist for type 2 diabetes FDA press release. The approved labeling contains the following load-bearing parameters:

• Semaglutide strengths: 7 mg and 14 mg tablets.
• SNAC content: 300 mg per tablet.
• Oral semaglutide absolute bioavailability: approximately 0.4% to 1%.
• Subcutaneous semaglutide bioavailability: 89% in the same label.
• Administration conditions: empty stomach, ≤4 ounces water, 30-minute waiting period.

Sources: Rybelsus FDA label.

This means that a 14 mg oral dose has a systemic absorption estimated at only 56 to 140 micrograms of semaglutide, depending on the bioavailability point used. The enhancer burden is high: 300 mg SNAC is needed to deliver a small peptide mass.

Mycapssa: oral octreotide

Mycapssa is an oral delayed-release octreotide capsule approved for acromegaly. The FDA drug-approval record lists approval on 2020-06-26 Drugs@FDA, NDA 208232. This product demonstrates that oral peptide delivery can reach regulatory approval beyond the GLP-1 category. The exact enhancer composition and mechanism in Mycapssa should be treated separately from SNAC; it is not a direct mechanistic twin of Rybelsus.

Broader clinical track record

The broader oral peptide field has produced many clinical failures. The peer-reviewed enhancer literature frames this accurately: enhancer-based formulations often improve absorption in preclinical models but fail in human trials because human intestinal differences, variability, and local toxicity are difficult to predict [Maher et al. 2016, DOI 10.1016/j.addr.2016.06.005]. Therefore, despite two FDA approvals, oral peptide delivery remains a high-risk technology domain.

Intellectual property landscape

The central granted patent cited here is:

• U.S. Patent No. 5,650,386 A — Emisphere Technologies, Inc., granted 1997-07-22. The patent record describes compositions and methods for oral delivery of active agents using enhancer compounds related to SNAC US5650386A.

This is a granted patent, not a patent application. Under the source-tier rules, a granted patent is Tier 1 for IP claims. It supports the existence of recorded Emisphere claims, but it does not support any clinical-performance claim. A patent is not proof that a product is safe, effective, or commercially viable.

Important distinction: later filings and continuing applications are likely to exist in the SNAC/oral semaglutide patent family. Those applications should not be cited as granted patents unless their grant numbers are verified. This note does not use application numbers for load-bearing IP claims.

The early Emisphere composition patent dates to 1997. Under a 20-year patent-term framework, the initial composition claims would likely be expired or close to expiration, depending on maintenance fees and terminal disclaimers. Therefore, present-day exclusivity for oral semaglutide/SNAC may depend on later-issued formulation, use, or method patents. A full freedom-to-operate analysis is outside this note and would require retrieval of the entire patent family. This is a source-bound limitation.

Worked calculations

Calculation 1: enhancer-to-peptide mass ratio in Rybelsus

This is a simple but useful formulation calculation based on regulatory specification data.

Formula:

\[

R_\text{mass} = \frac{m_\text{SNAC}}{m_\text{semaglutide}}

\]

Inputs from the FDA label Rybelsus FDA label:

• \(m_\text{SNAC} = 300\ \text{mg}\)
• \(m_\text{semaglutide} = 14\ \text{mg}\) for the high-strength tablet

Calculation:

\[

R_\text{mass,14mg} = \frac{300\ \text{mg}}{14\ \text{mg}} = 21.4

\]

Sensitivity:

\[

R_\text{mass,7mg} = \frac{300\ \text{mg}}{7\ \text{mg}} = 42.9

\]

Interpretation: the enhancer mass is 21.4 to 42.9 times the peptide mass. This is a high excipient-to-API ratio, which constrains tablet size, dissolution, local exposure, and manufacturing cost.

Source dependence: this calculation is derived from one FDA label. The calculation itself is arithmetic, but the inputs are [SINGLE-SOURCE] from the label.

Calculation 2: oral-to-subcutaneous absorbed mass equivalence

Formula:

\[

D_\text{abs} = D_\text{oral} \times F_\text{oral}

\]

\[

D_\text{subQ,eq} = \frac{D_\text{abs}}{F_\text{subQ}}

\]

Inputs from the FDA label Rybelsus FDA label:

• \(D_\text{oral} = 14\ \text{mg}\)
• \(F_\text{oral} = 0.004\) to \(0.01\)
• \(F_\text{subQ} = 0.89\)

Calculation at low oral bioavailability:

\[

D_\text{abs} = 14 \times 0.004 = 0.056\ \text{mg}

\]

\[

D_\text{subQ,eq} = \frac{0.056}{0.89} = 0.063\ \text{mg}

\]

At high oral bioavailability:

\[

D_\text{abs} = 14 \times 0.01 = 0.140\ \text{mg}

\]

\[

D_\text{subQ,eq} = \frac{0.140}{0.89} = 0.157\ \text{mg}

\]

Midpoint sensitivity, using \(F_\text{oral} = 0.007\):

\[

D_\text{abs} = 14 \times 0.007 = 0.098\ \text{mg}

\]

\[

D_\text{subQ,eq} = \frac{0.098}{0.89} = 0.110\ \text{mg}

\]

This calculation is an absorbed-mass equivalence only. It does not establish therapeutic equivalence to a specific subcutaneous semaglutide dose. Clinical dosing equivalence requires AUC, \(C_{\max}\), and pharmacodynamic data from controlled trials, not merely absolute-bioavailability arithmetic.

Parameter table

Unit economics / business model

The oral peptide enhancer business has historically been a licensing/platform model, not primarily a commodity-excipient model.

Emisphere Technologies monetized the SNAC/Eligen platform by licensing it to pharmaceutical partners. The specific royalty and milestone terms from the Novo Nordisk license were not retrieved from a primary SEC exhibit during this pass; therefore any specific royalty-rate figure is needs primary source validation. What can be stated from the corporate record is that the economics changed when Novo Nordisk acquired Emisphere — the enhancer IP was internalized rather than rented SEC EDGAR, Novo Nordisk A/S, CIK 0000901170.

After internalization, the economic value of SNAC is embedded in Rybelsus product revenue. Novo Nordisk captures the combined peptide-plus-enhancer value as a pharmaceutical product, not as a standalone SNAC sale. The high excipient mass per tablet — 300 mg SNAC per dose — means the enhancer is not a negligible cost input, but no verified public cost-of-goods figure for SNAC was retrieved. Any margin estimate would be needs primary source validation.

The historical licensing model is attractive because the enhancer owner can earn milestones and royalties without bearing full clinical development cost. However, the acquiring party captures the downstream product economics. The fact that an approved product sponsor acquired its enhancer supplier indicates that, for the most successful program, vertical integration prevailed over arm’s-length licensing.

Disconfirming evidence

The thesis that SNAC-class permeation enhancers are a commercially important and technically viable oral peptide delivery strategy would be weakened or refuted by:

1. Long-term clinical safety findings of sustained gastric or intestinal epithelial dysfunction. If postmarketing studies show progressive mucosal injury, nutrient malabsorption, or chronic permeability changes from SNAC-containing products, the benefit-risk profile would deteriorate. The mechanistic premise of a controlled, transient transcellular effect Buckley et al. 2018, DOI 10.1126/scitranslmed.aar7047 would be challenged.

1. Generic or alternative-enhancer bioequivalence without Emisphere-derived IP. If a generic oral semaglutide or another enhancer achieves bioequivalence without infringing current IP, the moat around the internalized SNAC platform would narrow. The early composition patent granted in 1997 US5650386A may already be expired, so future exclusivity depends on later patents.

1. Repeated clinical failures of next-generation oral peptides using similar enhancers. If oral PTH, oral insulin, or other enhancer-based peptides continue to miss endpoints, the addressable market would be limited to the few already-approved products, not a broad platform.

1. A demonstration that SNAC is not the primary absorption mechanism for oral semaglutide. If independent work shows that gastric absorption is primarily a function of semaglutide’s own physicochemical properties rather than SNAC, the enhancer’s commercial and technical significance would decline, even if Rybelsus remains a successful product.